15421-84-8
Chemical Structure
Trapidil
Synonym(s): AR-12008
- CAS No.: 15421-84-8
- Formula:C10H15N5
- Molecular Weight:205.26
IUPAC Name: N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
InChIKey: GSNOZLZNQMLSKJ-UHFFFAOYSA-N
SMILES: CC1=NC2=NC=NN2C(N(CC)CC)=C1
Biological Activity: Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury[1][2][3][4][5][6][7][8][9][14][23][29].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Trapidil | 98.0% | Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trapidil (Standard) | ≥98% | Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Avlan D, et al. Effects of trapidil on renal ischemia-reperfusion injury. J Pediatr Surg. 2006;41(10):1686-1693. [Content Brief]
- [2]. Colak T, et al. Effects of trapidil on intestinal mucosal barrier function and bacterial translocation after intestinal ischemia and reperfusion in an experimental rat model. Curr Ther Res Clin Exp. 2003;64(6):355-366. [Content Brief]
- [3]. Somuncu S, et al. Protective effects of trapidil in lung after abdominal aorta induced ischemia-reperfusion injury: an experimental study. Pediatr Surg Int. 2005;21(12):983-988. [Content Brief]
- [4]. Noha Shafik, et al. Effect of Triazolopyridine (Trapidil) on Experimental Hepatorenal Toxicity Induced by Renal Ischemia Reperfusion Injury in Rats. ed. J. Cairo Univ., Vol. 86, No. 5, September: 2159-2167, 2018.
- [5]. Bagdatoglu C, et al. Effect of trapidil in ischemia/reperfusion injury of peripheral nerves. Neurosurgery. 2002;51(1):212-220. [Content Brief]
- [6]. Somuncu S, et al. Trapidil, an inhibitor for phosphodiesterase and platelet-derived-growth factor, ameliorates corrosive esophageal burn in rats. Tohoku J Exp Med. 2005;207(3):203-208. [Content Brief]
- [7]. Razzaque MS, et al. Suppression of mesangial-cell proliferation by trapidil in glomerulonephritis induced by anti-thymocyte serum in rats. J Int Med Res. 1995 Nov-Dec;23(6):458-66. [Content Brief]
-
[8].
J. Beitz, et al. A New Derivative of Trapidil (AR 12456) as a Potentially New Antiatherosclerotic Drug. Cardiovascular Drug Reviews. Vol. 9, No. 4, pp. 385-397. - [9]. Todo T, et al. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. J Neurosurg. 1993;78(3):463-469. [Content Brief]
- [23]. Suzuki Y, et al. Antithrombotic activity and the mechanism of action of trapidil (Rocornal). Prostaglandins Leukot Med. 1982 Dec;9(6):685-95. [Content Brief]
- [29]. Maresta A, et al. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation. 1994 Dec;90(6):2710-5. [Content Brief]
